TNSN96025A1 - NEW ORAL PHARMACEUTICAL PRESENTATION - Google Patents
NEW ORAL PHARMACEUTICAL PRESENTATIONInfo
- Publication number
- TNSN96025A1 TNSN96025A1 TNTNSN96025A TNSN96025A TNSN96025A1 TN SN96025 A1 TNSN96025 A1 TN SN96025A1 TN TNSN96025 A TNTNSN96025 A TN TNSN96025A TN SN96025 A TNSN96025 A TN SN96025A TN SN96025 A1 TNSN96025 A1 TN SN96025A1
- Authority
- TN
- Tunisia
- Prior art keywords
- presentation
- formulation
- oral pharmaceutical
- pharmaceutical presentation
- new oral
- Prior art date
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
UNE PRESENTATION PHARMACEUTIQUE POUR ADMINISTRATION PAR VOIE BUCCALE COMPRENANT UN INHIBITEUR DE POMPE PROTONIQUE SENSIBLE A L'ACIDE ET UN OU PLUSIEURS COMPOSES ANTIBACTERIENS DANS UNE FORMULATION FIXE. LA FORMULATION FIXE EST DESTINEE A L'EMPLOI PAR VOIE BUCCALE ET SOUS LA FORME DE COMPRIMES A ENROBAGE A DELITEMENT ENTERIQUE ; SOUS LA FORME D'UNE GELULE; OU SOUS LA FORME DE COMPRIMES A UNITES MULTIPLES. LA PRESENTATION A UNITES MULTIPLES EST CELLE QUI EST PREFEREE. LA NOUVELLE FORMULATION A DOSE FIXE EST PARTICULIEREMENT UTILE DANS LE TRAITEMENT D'AFFECTIONS ASSOCIEES AUX INFECTIONS AU HELICOBACTER.A PHARMACEUTICAL PRESENTATION FOR ORAL ADMINISTRATION COMPRISING AN ACID SENSITIVE PROTONIC PUMP INHIBITOR AND ONE OR MORE ANTIBACTERIAL COMPOUNDS IN A FIXED FORMULATION. THE FIXED FORMULATION IS INTENDED FOR ORAL USE AND IN THE FORM OF DELICALLY ENTERIC COATED TABLETS; IN THE FORM OF A CAPSULE; OR IN THE FORM OF MULTIPLE UNIT TABLETS. THE PRESENTATION IN MULTIPLE UNITS IS THAT PREFERRED. THE NEW FIXED DOSE FORMULATION IS ESPECIALLY USEFUL IN THE TREATMENT OF CONDITIONS ASSOCIATED WITH HELICOBACTER INFECTIONS.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9500422A SE9500422D0 (en) | 1995-02-06 | 1995-02-06 | New oral pharmaceutical dosage forms |
Publications (1)
Publication Number | Publication Date |
---|---|
TNSN96025A1 true TNSN96025A1 (en) | 2005-03-15 |
Family
ID=47598445
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TNTNSN96025A TNSN96025A1 (en) | 1995-02-06 | 1996-02-05 | NEW ORAL PHARMACEUTICAL PRESENTATION |
Country Status (3)
Country | Link |
---|---|
KR (1) | KR100399524B1 (en) |
TN (1) | TNSN96025A1 (en) |
YU (1) | YU7396A (en) |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5128140A (en) * | 1991-01-14 | 1992-07-07 | The Procter & Gamble Company | Swallowable pharmaceutical compositions |
-
1996
- 1996-02-02 KR KR1019960705556A patent/KR100399524B1/en not_active IP Right Cessation
- 1996-02-05 TN TNTNSN96025A patent/TNSN96025A1/en unknown
- 1996-02-06 YU YU7396A patent/YU7396A/en unknown
Also Published As
Publication number | Publication date |
---|---|
YU7396A (en) | 1998-08-14 |
KR100399524B1 (en) | 2004-04-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TNSN98059A1 (en) | SELECTIVE COX-2 INHIBITOR COMPOUNDS, ANTI-INFLAMMATORY AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME. | |
Shaw | Causes and control of dental caries | |
TNSN96024A1 (en) | NEW PHARMACEUTICAL COMBINATION | |
AU6770490A (en) | Solid pharmaceutical compositions containing cimetidine | |
BE901667A (en) | ANALGESIC AND ANTI-INFLAMMATORY COMPOSITION BASED ON DIPHENHYDRAMINE, THEIR PREPARATION AND THEIR USE. | |
DZ1078A1 (en) | Pharmaceutical formulation of acid labile substance for oral administration. | |
CA2134196A1 (en) | Pharmaceutical preparation and process for its manufacture | |
TNSN97139A1 (en) | DERIVATIVES OF ARYLSULFONYLAMINOHYDROXAMIC ACIDS | |
DE3686936D1 (en) | ENTERAL DELIVERY SYSTEM ACTIVE ON THE TARGET ORGAN. | |
NO975218L (en) | Treatment of inflammatory bowel disease using oral dosage forms of omega-3 polyunsaturated acids | |
DE68920578D1 (en) | Various types of pharmaceuticals containing orally administered cellulose ether with controlled release of active ingredients. | |
BE899885A (en) | NAPROXEN AND NAPROXEN SODIUM TABLETS WITH CONTROLLED RELEASE. | |
KR950031069A (en) | How to suppress bone loss and lower serum cholesterol | |
TNSN98229A1 (en) | EXTENDED RELEASE ORAL PHARMACEUTICAL FORMULATION | |
RU94026283A (en) | Pharmaceutical compound | |
JPH01279838A (en) | Lysozyme chloride-containing plaster for gingivitis and pyorrhea | |
BE901073A (en) | ANTIDIURETIC COMPOSITION FOR ORAL USE. | |
IT1256697B (en) | MEDICATIONS TO TREAT INFLAMMATORY CONDITIONS OR ANALGESIA. | |
KR910014124A (en) | Swallowable Dosage Units Containing Colloidal Bismuth Subcitrate (CBS) | |
IT1238072B (en) | PHARMACEUTICAL COMPOSITIONS AND DOSAGE FORMS FOR ORAL ADMINISTRATION OF CALCITONIN | |
TNSN96025A1 (en) | NEW ORAL PHARMACEUTICAL PRESENTATION | |
IT8820172A0 (en) | AMIDES OF CYCLOMETHYLEN_1,2_DICARBOXYLIC ACIDS THERAPEUTIC SUITABILITY, PROCEDURES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM. | |
BE1002295A5 (en) | DRUGS. | |
BE1002255A5 (en) | DRUGS. | |
FR2363324A1 (en) | AQUEOUS OR HYDROALCOOLIC STABLE SOLUTIONS OF PERFUMED ESSENCES OR OIL SOLUBLE MEDICINAL PRODUCTS |